Jasper Therapeutics
JSPR
69 hedge funds and large institutions have $330M invested in Jasper Therapeutics in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 18 closing their positions.
215% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $1.03M
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
13% more funds holding
Funds holding: 61 → 69 (+8)
10.01% more ownership
Funds ownership: 86.51% → 96.52% (+10%)
13% less capital invested
Capital invested by funds: $380M → $330M (-$50.4M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13.9M |
| 2 |
BlackRock
New York
|
+$12M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.66M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.63M |
| 5 |
Morgan Stanley
New York
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$5.12M |
| 2 |
Millennium Management
New York
|
-$2.12M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$1.71M |
| 4 |
Jane Street
New York
|
-$1.23M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.22M |
JSPR Hedge Fund Activity: Q2 2024 in Review
69 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2024, worth a combined $330M — down 13% from $380M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new JSPR positions and 18 closed out — a net gain of 8 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $13.9M. The largest seller was Octagon Capital Advisors, cutting an estimated $5.12M.
- 69 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2024, up from 61 in Q1 2024.
- Funds reported $330M of Jasper Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
- 26 funds opened new Jasper Therapeutics positions in Q2 2024 and 18 closed out, a net change of +8 holders.
- The largest Jasper Therapeutics buyer in Q2 2024 was Polar Capital Holdings, an estimated $13.9M added.
- The largest Jasper Therapeutics seller in Q2 2024 was Octagon Capital Advisors, an estimated $5.12M sold.
Based on aggregated 13F filings for Q2 2024.